Market Overview:
The global genetic vaccine market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth of the market can be attributed to the increasing prevalence of infectious diseases, rising demand for preventive vaccines, and technological advancements in the field of genetic vaccines. The recombinant protein vaccine segment is expected to dominate the global genetic vaccine market during the forecast period. This segment is anticipated to grow at a CAGR of 11% from 2018 to 2030. The gene-based vaccine segment is projected to grow at a CAGR of 12% from 2018to 2030 owingto its advantages over traditional vaccines such as high specificity and safety. However, this typeofvaccineis still in developmental stagesand has not been approved by regulatory authorities such asthe U S Food and Drug Administration (FDA). In terms of application, human applications are expectedtogrowat amuch higherCAGRthan animal applications duringthe forecast period.
Product Definition:
A genetic vaccine is a vaccine that uses pieces of DNA to help the body build immunity to a disease. Genetic vaccines are made from pieces of the virus' or bacteria's DNA. When introduced into the body, these pieces help program cells to recognize and fight off infection from the virus or bacteria.
Recombinant Protein Vaccine:
Recombinant protein vaccine is a new type of vaccine that uses an animal-derived recombinant protein as the antigen. The first recombinant protein vaccines were developed in the early 1990s and have been commercialized since then. Recombinant proteins are used because they are safer than other types of viral proteins; they do not cause disease when consumed by humans.
Gene-Based Vaccine:
A gene-based vaccine is a type of vaccine that uses the genetic material (DNA or RNA) from an infectious agent to stimulate the body's immune system to fight off diseases. The most common way of producing gene-based vaccines is by using DNA as a carrier for the disease-causing microorganism's genes.
Application Insights:
Based on application, the global market is segmented into human, animal and plant-based vaccines. The human vaccine segment dominated the overall market in terms of revenue as well as volume in 2017. This can be attributed to increasing incidences of diseases such as tuberculosis, chickenpox and others that are caused by bacteria or viruses and can be treated by immunization with DNA or RNA-based vaccines.
Plant-based genetic vaccines are expected to witness significant growth over the forecast period owing to their potential use against crop pests that cause damage worth millions of dollars each year leading to a rise in demand for GVH products among farmers across the globe.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a substantial number of players, increasing focus on novel vaccines, and rising incidence of infectious diseases. The U.S.-based companies are involved in extensive R&D activities for developing new generation vaccines that are free from numerous side effects associated with conventional vaccination methods thus making it an attractive regional market for investors.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to growing target population base along with rapidly improving healthcare infrastructure.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. Genetic vaccines can play a major role in preventing and managing these chronic diseases.
- Growing demand for personalized medicines: There is a growing demand for personalized medicines across the world. This is because every individual has a unique genetic makeup that requires specific treatment approaches. Genetic vaccines can help meet this demand by providing customized therapies to patients based on their genetic profiles.
- Advances in biotechnology: The field of biotechnology is advancing rapidly, with new technologies being developed all the time to improve our understanding of genetics and how they influence health and disease processes. This progress will undoubtedly lead to further advances in genetic vaccine technology, making them even more effective at preventing and treating disease conditions in the future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Genetic Vaccine Market Research Report
By Type
Recombinant Protein Vaccine, Gene-Based Vaccine,
By Application
Human, Animal,
By Companies
Merck, GSK, Sanofi, Zoties, Elanco, Boehringer-Ingelheim, Indian Immunologicals, Plumbline Life Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Genetic Vaccine Market Report Segments:
The global Genetic Vaccine market is segmented on the basis of:
Types
Recombinant Protein Vaccine, Gene-Based Vaccine,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Human, Animal,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- GSK
- Sanofi
- Zoties
- Elanco
- Boehringer-Ingelheim
- Indian Immunologicals
- Plumbline Life Sciences
Highlights of The Genetic Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Recombinant Protein Vaccine
- Gene-Based Vaccine
- By Application:
- Human
- Animal
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genetic Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A genetic vaccine is a vaccine that uses pieces of the person's own DNA to help protect them from disease. This type of vaccine works by helping the body build immunity against a particular disease.
Some of the major players in the genetic vaccine market are Merck, GSK, Sanofi, Zoties, Elanco, Boehringer-Ingelheim, Indian Immunologicals, Plumbline Life Sciences.
The genetic vaccine market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Genetic Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Genetic Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Genetic Vaccine Market - Supply Chain
4.5. Global Genetic Vaccine Market Forecast
4.5.1. Genetic Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Genetic Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Genetic Vaccine Market Absolute $ Opportunity
5. Global Genetic Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Genetic Vaccine Market Size and Volume Forecast by Type
5.3.1. Recombinant Protein Vaccine
5.3.2. Gene-Based Vaccine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Genetic Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Genetic Vaccine Market Size and Volume Forecast by Application
6.3.1. Human
6.3.2. Animal
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Genetic Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Genetic Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Genetic Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Genetic Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Genetic Vaccine Demand Share Forecast, 2019-2026
9. North America Genetic Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Genetic Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Genetic Vaccine Market Size and Volume Forecast by Application
9.4.1. Human
9.4.2. Animal
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Genetic Vaccine Market Size and Volume Forecast by Type
9.7.1. Recombinant Protein Vaccine
9.7.2. Gene-Based Vaccine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Genetic Vaccine Demand Share Forecast, 2019-2026
10. Latin America Genetic Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Genetic Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Genetic Vaccine Market Size and Volume Forecast by Application
10.4.1. Human
10.4.2. Animal
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Genetic Vaccine Market Size and Volume Forecast by Type
10.7.1. Recombinant Protein Vaccine
10.7.2. Gene-Based Vaccine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Genetic Vaccine Demand Share Forecast, 2019-2026
11. Europe Genetic Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Genetic Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Genetic Vaccine Market Size and Volume Forecast by Application
11.4.1. Human
11.4.2. Animal
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Genetic Vaccine Market Size and Volume Forecast by Type
11.7.1. Recombinant Protein Vaccine
11.7.2. Gene-Based Vaccine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Genetic Vaccine Demand Share, 2019-2026
12. Asia Pacific Genetic Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Genetic Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Genetic Vaccine Market Size and Volume Forecast by Application
12.4.1. Human
12.4.2. Animal
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Genetic Vaccine Market Size and Volume Forecast by Type
12.7.1. Recombinant Protein Vaccine
12.7.2. Gene-Based Vaccine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Genetic Vaccine Demand Share, 2019-2026
13. Middle East & Africa Genetic Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Genetic Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Genetic Vaccine Market Size and Volume Forecast by Application
13.4.1. Human
13.4.2. Animal
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Genetic Vaccine Market Size and Volume Forecast by Type
13.7.1. Recombinant Protein Vaccine
13.7.2. Gene-Based Vaccine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Genetic Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Genetic Vaccine Market: Market Share Analysis
14.2. Genetic Vaccine Distributors and Customers
14.3. Genetic Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GSK
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Zoties
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Elanco
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Boehringer-Ingelheim
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Indian Immunologicals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Plumbline Life Sciences
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
